Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NGD 97-1: Began Phase II testing

Neurogen Corp. (NRGN), Branford, Conn.
Product: NGD 97-1

Read the full 80 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE